Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Phase I/Ib Trial of Single Agent PBF-509 and in Combination With PDR001 for Patients With Advanced NSCLC

NCT02403193 is registered in ClinicalTrials.gov with Palobiofarma SL as lead sponsor.

NCT NCT02403193
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02403193 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Phase I/Ib Trial of Single Agent PBF-509 and in Combination With PDR001 for Patients With Advanced NSCLC
Lead sponsor
Palobiofarma SL
Phase
Phase 1
Overall status
Completed
Start date
October 31, 2015
Completion date
November 24, 2021
Enrollment
92 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

non-small cell lung cancer (nsclc)